Alzamend Neuro, Inc.
Alzamend Neuro, Inc.
- Market cap
- $3.74M
Your view on ALZN
Overview
What the company does, where it operates, and who runs it.
About Alzamend Neuro, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Stephan Jackman
- Headquarters
- 3500 Lenox Road NE, Atlanta, GA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Stephan Jackman
- Headquarters
- 3500 Lenox Road NE, Atlanta, GA, US
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.
The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Alzamend Neuro, Inc.. Starting points for Alzamend Neuro, Inc.: EPS -$2.03, beta 0.19 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Alzamend Neuro, Inc.. Trailing twelve-month EPS for Alzamend Neuro, Inc. stands at -$2.03. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Alzamend Neuro, Inc.. Alzamend Neuro, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| REPCFRepliCel Life Sciences Inc. | Healthcare | OTC | $7,358 | ||
| REPLReplimune Group, Inc. | Healthcare | NASDAQ | $1.8B | ||
| REVBRevelation Biosciences, Inc. | Healthcare | NASDAQ | $2.0M | ||
| REVBWRevelation Biosciences, Inc. | Healthcare | NASDAQ | $27,251 | ||
| RGBPRegen BioPharma, Inc. | Healthcare | OTC | $37,866 | ||
| RGBPPRegen BioPharma, Inc. | Healthcare | OTC | $89,893 | ||
| RGINRegenicin, Inc. | Healthcare | OTC | $15,348 | ||
| RGNXREGENXBIO Inc. | Healthcare | NASDAQ | $473.4M | ||
| RGRXRegeneRx Biopharmaceuticals, Inc. | Healthcare | OTC | $449 | ||
| RIGLRigel Pharmaceuticals, Inc. | Healthcare | NASDAQ | $754.9M | ||
| RLAYRelay Therapeutics, Inc. | Healthcare | NASDAQ | $3.6B | ||
| RLFTFRelief Therapeutics Holding AG | Healthcare | OTC | $11.9M | ||
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Alzamend Neuro, Inc., and how their positions are changing. At a $3.7M market value, institutional positions materially move Alzamend Neuro, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Alzamend Neuro, Inc. executives and directors. Shares of Alzamend Neuro, Inc. have traded between $2.06 and $12.60 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Alzamend Neuro, Inc.. Coverage tracks Alzamend Neuro, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Alzamend Neuro, Inc.